Precigen Inc
Research Precigen Inc (PGEN) on Bullrun: market cap USD 2.61B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPGEN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.61B
- Financial periodQ2 2026
- RevenueUSD 54.98M
- Net incomeUSD 20.07M
- Free cash flow-USD 18.20M
- Gross margin94.9%
Valuation Snapshot
latest market cap is USD 2.61B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 9.68M | -USD 250.60M | -USD 89.83M | 50.2% | -1.37 | USD 30.23M | USD 93.17M | USD 20.91M |
| FY2024 | USD 3.93M | -USD 126.20M | -USD 76.76M | -8.7% | -0.47 | USD 29.52M | USD 0 | USD 38.51M |
| FY2023 | USD 6.23M | -USD 95.90M | -USD 68.47M | n/a | -0.39 | USD 7.58M | USD 0 | USD 118.50M |
| FY2022 | USD 26.91M | USD 28.30M | -USD 69.97M | n/a | 0.14 | USD 4.86M | USD 43.22M | USD 126.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.61B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.48B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 328.01M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 333.55M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 316.39M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 767.01M | n/a | n/a | n/a |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Precigen Inc's market cap?
Precigen Inc's market capitalization is USD 2.61B.
What does Precigen Inc do?
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.